Guelfi 1998a.

Methods	12 week randomised double blind study
Participants	Diagnosis: Inpatients with DSM‐III‐R major depression Male and Female. Threshold of baseline severity: HDRS‐17>=22, Newcastle scale>=6, HDRS specific endogenous subscale>=8 Total number of all allocated participants: N=300 Age: mean 45.6 (SD 12.8)y for milnacipran 100mg, mean 45.2 (SD 12.5)y for milnacipran 200mg, mean 45.8 (SD 12.8)y for fluoxetine; range 18‐70y
Interventions	Milnacipran 100/200mg: N=200 (100mg:N=100, 200mg:N=100) Fluoxetine 20mg: N=100 Fixed dosing schedule.
Outcomes	Hamilton Depression Rating Scale‐17 item, MADRS, CGI‐S
Notes	Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "randomised". Probably done.
Allocation concealment (selection bias)	Unclear risk	Insufficient information.
Blinding (performance bias and detection bias) All outcomes	Low risk	Quote: "double‐blind"
Incomplete outcome data (attrition bias) All outcomes	High risk	Missing primary outcome data at early phase.
Selective reporting (reporting bias)	High risk	Some missing standard deviations.
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists.